| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human EPHA4 was used as the immunogen for the EPHA4 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
EPHA4 Antibody / Ephrin type-A receptor 4 is a anti-EPHA4 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB) with listed reactivity in Human.
Key elements and design rationale
- Target: EPHA4
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB
Biological background
EPHA4 is encoded by the EPHA4 gene on human chromosome 2q36.1. The receptor consists of an extracellular ligand-binding domain, a cysteine-rich region, two fibronectin type III repeats, a single transmembrane domain, and an intracellular kinase domain. EPHA4 binds both ephrin-A and ephrin-B ligands, enabling cross-class signaling that regulates axonal navigation, synaptic plasticity, and tissue boundary formation.
The EPHA4 antibody detects a 120-130 kilodalton transmembrane receptor by western blot. Activation of EPHA4 by ephrin ligands triggers receptor autophosphorylation, recruitment of adaptor proteins, and cytoskeletal reorganization via Rho GTPase signaling. This leads to growth cone collapse and repulsion, essential for proper neural circuit formation.
In the central nervous system, EPHA4 influences axon pathfinding in the corticospinal tract and regulates synapse formation and plasticity. It is also implicated in spinal cord injury response, where its inhibition promotes axonal regeneration. Outside the nervous system, EPHA4 modulates angiogenesis, epithelial morphogenesis, and tumor progression. Overexpression has been observed in breast, prostate, and colorectal cancers, correlating with invasive behavior and poor prognosis.
EPHA4 signaling crosstalks with pathways including MAPK, PI3K-Akt, and JAK-STAT, integrating environmental cues with cell motility and survival. Genetic ablation in animal models results in abnormal axon targeting and motor coordination defects.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
